Introduction
============

Lung cancer is the leading cause of cancer death worldwide, and non-small cell lung cancer (NSCLC) that consists mainly of squamous cell carcinoma (SCC) and adenocarcinoma (AD) accounts for nearly 80% of all lung cancer cases.[@b1-cmar-9-381] Thus, understanding of the mechanisms of lung carcinogenesis in the NSCLC subtypes is urgently needed.

The silent information regulator 2 (Sir2) family is a highly conserved group of genes from bacteria to humans and encodes a group of nicotinamide adenine dinucleotide (NAD^+^)-dependent histone deacetylases.[@b2-cmar-9-381] In mammalian cells, there are seven homologues (Sirts 1--7) of yeast Sir2, termed sirtuins, which share the catalytic domain with Sir2.[@b3-cmar-9-381] *Sirt1*, which is located in the long arm of chromosome 10 (10q21.3) and consists of nine exons and eight introns, is the closest homologue of yeast Sir2.[@b4-cmar-9-381]--[@b6-cmar-9-381] Many studies have shown that SIRT1 regulates a wide variety of cellular functions, such as mitochondrial biogenesis, autophagy, circadian rhythms, stress resistance, apoptosis, and glucose and lipid metabolism.[@b7-cmar-9-381]--[@b9-cmar-9-381] *SIRT1* gene has been extensively studied, and was shown to be implicated in cancer, inflammation, obesity, diabetes, and cardiovascular and neurodegenerative diseases.[@b10-cmar-9-381]--[@b12-cmar-9-381] *SIRT1* deacetylates various transcription factors that are involved in stress response, cell cycle and apoptosis, such as p53, Ku70, nuclear factor kB, FOXO and HIC1.[@b13-cmar-9-381]--[@b18-cmar-9-381] Animal studies demonstrated that SIRT1 was essential to the embryonic development.[@b15-cmar-9-381],[@b19-cmar-9-381] On the other hand, accumulating evidence showed that SIRT1 was overexpressed in various types of malignant cells, and its inhibitors suppressed the growth of tumor cells.

To date, polymorphisms in *SIRT1* have been associated with several disease-related phenotypes, including diabetes, body mass index, obesity, cholesterol metabolism, energy expenditure, glucose tolerance and cardiovascular disease.[@b20-cmar-9-381] However, very little is known about the association of polymorphism of *SIRT1* and lung cancer development in the Chinese Han population. Based on the previous reports, we hypothesized that polymorphisms in *SIRT1* might also be associated with susceptibility to lung cancer. Therefore, four functional single-nucleotide polymorphisms (SNPs) were selected for further investigation of their association with lung cancer.

Patients and methods
====================

Subject selection
-----------------

We conducted a retrospective study using in-patient medical records of patients with NSCLC who were treated at Zhejiang Hospital in China. The case--control study consisted of 257 patients with NSCLC and 246 controls. The records of 257 patients with NSCLC admitted to Zhejiang Hospital between January 2010 and June 2015 were reviewed based on the following inclusion criteria: 1) patient was pathologically diagnosed with NSCLC; 2) patient displayed normal cardiac functions and 3) patient displayed normal serum glucose level. Exclusion criteria were the following: 1) patient with small cell lung cancer and 2) patient with malignant tumors except lung cancer.

All participants were provided written informed consent. Our study protocol was approved by the Ethics Committee of Zhejiang Hospital (No. 2013-k-2), and all experiments were conducted in accordance with the Declaration of Helsinki.

SNP selection and genotyping
----------------------------

The candidate SNPs were selected based on the relevant studies of the SNPs associated with human diseases, combined the result analyses by Haploview 4.2 software r^2^≥0.8 and the allele frequency in public database of the National Center for Biotechnology Information (a minor allele frequency ≥0.05) (<http://www.ncbi.nlm.nih.gov/snp/>) in *SIRT1* gene region (Gene ID: 23411). We downloaded the China Han population's SNP data of *SIRT1* gene from HapMap data-base (HapMap Genome Browser \[phases 1, 2 and 3 merged genotypes and frequencies\]). We then analyzed these data by Haploview 4.2 software. We found four TagSNPs with *r*^2^≥0.8 and a minor allele frequency ≥0.05: rs12778366 (C/T, lies in the 5′ upstream), rs3758391 (C/T, lies in the 5′ upstream), rs2273773 (C/T, lies in the coding) and rs4746720 (C/T, lies in the 3′ untranslated region \[UTR\]). Because that the four SNPs (tagSNPs) could capture all the SNPs with minor allele frequency ≥0.05 across the *SIRT1* gene region. We then conducted a further analysis about the four TagSNPs for their predicted functions by the online software FASTSNP (a web server that allows users to efficiently identify and prioritize high-risk SNPs according to their phenotypic risks and putative functional effects; FASTSNP is available at <http://fastsnp.ibms.sinica.edu.tw>.; [Table 1](#t1-cmar-9-381){ref-type="table"}).

Genotyping was carried out by ligase detection reaction (LDR). The target DNA sequences were amplified using a multiplex polymerase chain reaction method (the primer and probe sequence are shown in [Table 1](#t1-cmar-9-381){ref-type="table"}). LDR (2 min at 95°C, and 15 s at 94°C, 25s at 50°C, for 40 cycles) was proceeded in a final volume of 10 μL, which contained 1 μL 1× New England Biolabs (NEB) buffer for Taq DNA Ligase (New England Biolabs, Beverly, MA, USA), 1 mL of 2 pmol/μL of each common probe, 4 μL of Multi-polymerase chain reaction product and 0.5 μL of 2 U/μL Taq DNA Ligase. The fluorescent products of LDR were differentiated by ABI 377 sequencer (Perkin-Elmer, Foster City, CA, USA). The result was analyzed by GeneMapper Analysis Software 3.7 (Applied Biosystems, Foster City, CA, USA). The primer sequences are shown in the [Table 1](#t1-cmar-9-381){ref-type="table"}.

Statistical analysis
--------------------

The *χ*^2^ test was used to compare the distribution of the genotypes between lung cancer patients and controls using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Haploview 4.2 was used to calculate and display linkage disequilibrium (LD) values between the four SNPs. Hardy--Weinberg equilibrium test, genotype frequencies and LD were calculated using the SNPstats software (a web tool for the analysis of association studies: <http://bioinfo.iconcologia.net/SNPstats>).[@b21-cmar-9-381] The odds ratio and 95% CI were calculated to evaluate the risk between genotype frequencies and lung cancer. LD between SNPs was measured by calculating *r*^2^ values. All tests were two-sided, and a *P* value \<0.05 was considered statistically significant.

Results
=======

Of the four SNPs genotyped within the lung cancer cases and controls, all achieved a success rate of ≥85%, with an average success rate of 98.2% by LDR detection. A total of 257 NSCLC patients (200 men and 57 women) comprising 79 SCC patients (71 men and 8 women), 124 AD patients (77 men and 47 women) and 246 healthy individuals as controls (186 men and 60 women) were included in the study. The genotype frequencies of SNPs in all the groups did not deviate significantly from the expected values under the Hardy--Weinberg equilibrium (*P*\>0.05). LD of *SIRT1* polymorphism analysis using *r*^2^ within the case and control samples did not reveal strong LD ([Figure 1](#f1-cmar-9-381){ref-type="fig"}).

The genotype and allele frequencies for *SIRT1* polymorphisms in NSCLC, SCC, AD and control groups are shown in [Table 2](#t2-cmar-9-381){ref-type="table"}. We found no significant differences between the NSCLC cases, SCC cases, AD cases and controls for the four *SIRT1* polymorphisms when the general distribution of genotypes was compared. Haplotype (TTTC, TTCT, TCTT, CTTT) association analysis carried out on the four SNPs within the case--control cohort also did not reveal a significant association to lung cancer (*P*\>0.05, data not shown).

Discussion
==========

The *SIRT1* is located on the long arm of chromosome 10 (10q21.3). It has been shown to play crucial roles in mammalian health and disease and is often associated with the most complex physiologic processes such as metabolism, cancer and aging due to its NAD^+^-dependent deacetylase activity.[@b22-cmar-9-381] The mammalian *SIRT1* regulates several transcription factors that control the expression of genes involved in the metabolism and endocrine signaling, such as PPARg, PGC1-a, UCP2, NFkB and FOXO1 proteins, and plays important roles in glucose homeostasis and insulin secretion.[@b23-cmar-9-381]--[@b25-cmar-9-381] In the human *SIRT1* gene, multiple variants have been described, several of which are associated with carotid atherosclerosis, body mass index, aging, type 2 diabetes and risk of obesity.[@b26-cmar-9-381]--[@b31-cmar-9-381] However, very few *SIRT1* variants have been reported in lung cancer. Therefore, the main objective of this study was to identify the SNPs in *SIRT1* and to estimate the extent of associations between these SNPs and NSCLC.

Overexpression of SIRT1 or treating with *SIRT1* activators improves glucose homeostasis and insulin sensitivity in mice.[@b22-cmar-9-381],[@b32-cmar-9-381],[@b33-cmar-9-381] Li et al[@b34-cmar-9-381] observed a significant association between the C.−274C\>G polymorphism and growth traits in Nanyang cattle. They found that the G allele-containing construct displayed a strikingly lower promoter activity compared with the C allele by the luciferase assay system. In addition, they also found g.17379 A\>G polymorphism was significantly related to body weight of 6 and 12 months old in NY population.[@b35-cmar-9-381] Kilic et al[@b36-cmar-9-381] reported that the oldest people carrying AG genotypes for rs7895833 have the highest SIRT1 level, suggesting an association between rs7895833 SNP and lifespan longevity. The 2827 A\>G polymorphism is positioned on exon 2, leading to a histidine-to-arginine conversion. Although Izmirli et al[@b6-cmar-9-381] found no statistically significant relation between the 2827 A\>G at the *SIRT1* and cardiovascular disease, Peeters et al[@b37-cmar-9-381] reported that *SIRT1* rs7895833 and rs7069102 polymorphisms were associated with cardiovascular disease. Shimoyama et al[@b38-cmar-9-381] reported that the different allele frequencies in rs7895833 and rs7069102 between hemodialysis patients and controls could have an impact on the survival of Japanese hemodialysis patients.

Very little is known about the effect of polymorphism of *SIRT1* gene on lung cancer until now, despite the fact that many studies had been carried out on the association between the SNPs of *SIRT1* and human diseases. In this study, we assessed whether genetic variations in *SIRT1* are associated with NSCLC, which consists mainly of SCC and AD and accounts for nearly 80% of all lung cancer cases. According to our previous report,[@b39-cmar-9-381] the expression of SIRT1 was significantly associated with unfavorable SCC characteristics, but not with AD characteristics; furthermore, we compared the SNP frequencies in SCC patients vs controls and AD patients vs controls. We investigated four TagSNPs: rs12778366 (C/T, lies in the 5′ upstream), rs3758391 (C/T, lies in the 5′ upstream), rs2273773 (C/T, lies in the coding) and rs4746720 (C/T, lies in the 3′ UTR), which could capture all the SNPs with minor allele frequency ≥0.05 across the *SIRT1* gene region in 257 NSCLC patients (200 men and 57 women), 79 SCC patients (71 men and 8 women), 124 AD patients (77 men and 47 women) and 246 healthy controls (186 men and 60 women). By LDR detection, we achieved a success rate of 98.2% for the four Tag-SNPs. However, no association was detected between the SNP rs3758391 and NSCLC in Chinese population, which was similar to the previous study that reported no significant relationship between the SNP rs3758391 and extreme aging in Germans.[@b40-cmar-9-381],[@b41-cmar-9-381] Although in another study, rs3758391/C was found more common than rs3758391/T (*P*=0.026) and rs3758391/CC was more common than rs3758391/CT and rs3758391/TT (*P*=0.027) in the aging subjects.[@b42-cmar-9-381] The difference might be due to the different genetic background in different populations. rs4746720, which is located in the 3′ UTR, was also a TagSNP of *SIRT1* gene in Chinese Han population. Besides, Zhang et al[@b42-cmar-9-381] found that rs4746720/C was more common than rs4746720/T (*P*=0.022) and rs4746720/CC was more common than rs4746720/CT and rs4746720/TT (*P*=0.049) in the aging subjects. In contrast, our study did not find rs4746720 as a significant marker for lung cancer in the case--control analysis. Figarska et al[@b30-cmar-9-381] showed an association between the SNP rs12778366 in *SIRT1* gene and long-term survival in 1390 subjects of the Vlagtwedde/Vlaardingen cohort. Rai et al[@b43-cmar-9-381] sequenced the 1.46 kb region upstream of the translation start site of the *SIRT1* gene in 1542 samples (692 type 2 diabetes patients and 850 controls) in the North Indian population and observed that rs12778366 (lies in the promoter region of *SIRT1*) was associated with SIRT1 expression. However, in our case--control study, we did not find any relationship of the rs12778366 polymorphism in the NSCLC and control groups, SCC and control groups and AD and control groups. In addition, Flachsbart et al[@b41-cmar-9-381] studied the relationship between five SNPs (rs3758391, rs1885472, rs2273773, rs10997870 and rs2234975) in *SIRT1* gene in 1026 unrelated German long-lived individuals (mean age: 98.3 years) and found no association between *SIRT1* gene polymorphisms and exceptional human longevity. In our study, we also did not find any effect of the rs2273773 polymorphism in the NSCLC and control groups, SCC and control groups, AD and control groups.

The haplotypes (TTTC, TTCT, TCTT, CTTT) observed here are likely to represent some of the variation in the *SIRT1* genomic region in the population analyzed. In this study, we found no relationship of the haplotypes of the *SIRT1* in the NSCLC and control groups, SCC and control groups, AD and control groups.

To the best of our knowledge, this is the first report about the polymorphism of *SIRT1* and lung cancer. In our study, we found no significant association between *SIRT1* gene polymorphisms and human NSCLC, since we did not find any significant polymorphism of the *SIRT1* gene in the NSCLC and control groups, SCC and control groups, AD and control groups. The findings presented here may be due to the small number of the cases and controls, which is the main limitation of our study, due to the complex multifactorial genetic contribution to lung cancer. Expanding the sample size might be able to find a more meaningful result. Therefore, further studies with more sample size and subtle design are still necessary to delineate the functional roles of *SIRT1* polymorphism on lung cancer.
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###### 

The primer sequences and predicted functions for *SIRT1* gene polymorphisms

  SNP          Location      Risk[\*](#tfn1-cmar-9-381){ref-type="table-fn"}   Predicted function[\*](#tfn1-cmar-9-381){ref-type="table-fn"}   Primer sequence (5′--3′)
  ------------ ------------- ------------------------------------------------- --------------------------------------------------------------- ---------------------------------
  rs12778366   5′ Upstream   Unknown--unknown (0--0)                           Upstream with no known function                                 Sense: TAAGGCTTCTAGGACTGGAG
                                                                                                                                               Antisense: CTAAGGTCCTATCTACATCC
  rs3758391    5′ Upstream   Very low--medium (1--3)                           Promoter/regulatory region                                      Sense: GCACACTGTGACTCCATATC
                                                                                                                                               Antisense: GCCATAACAAACACTGGCTC
  rs2273773    Coding        Very low--very low (1--1)                         Sense/synonymous                                                Sense: TGGGTATAGTTGCGAAGTAG
                                                                                                                                               Antisense: TGGACAATTCCAGCCATCTC
  rs4746720    3′ UTR        Unknown--unknown (0--0)                           Downstream with no known function                               Sense: AGTTAGCTGCCACAGTTTTG
                                                                                                                                               Antisense: GTACTCAAAATCTGTTACGC

**Note:**

Analyzed by the online software FASTSNP (a web server that allows users to efficiently identify and prioritize high-risk SNPs, according to their phenotypic risks and putative functional effects).

**Abbreviations:** SNP, single-nucleotide polymorphism; *SIRT1*, the silent information regulator 1; UTR, untranslated region.

###### 

Association between *SIRT1* polymorphisms and NSCLC, SCC or AD

               Control (n=246), n (%)   NSCLC (n=257), n (%)   NSCLC vs control    SCC (n=79), n (%)   SCC vs control   AD (n=124), n (%)   AD vs control                                     
  ------------ ------------------------ ---------------------- ------------------- ------------------- ---------------- ------------------- --------------- ------------ -------------------- ------
  *SIRT*1                                                                                                                                                                                     
  rs12778366                                                                                                                                                                                  
  TT           186 (75.6)               189 (73.5)             1.00                                    64 (81)          1.00                                87 (70.7)    1.00                 
  TC           56 (22.8)                61 (23.7)              1.07 (0.71--1.63)   0.66                14 (17.7)        0.76 (0.39--1.47)   0.65            31 (25.2)    1.12 (0.67--1.87)    0.32
  CC           4 (1.6)                  7 (2.7)                1.72 (0.50--5.98)                       1 (1.3)          0.62 (0.07--5.62)                   5 (4.1)      2.78 (0.72--10.73)   
  rs3758391                                                                                                                                                                                   
  TT           179 (72.8)               178 (69.3)             1.00                                    56 (70.9)        1.00                                80 (65)      1.00                 
  TC           62 (25.2)                72 (28)                1.17 (0.78--1.74)   0.66                21 (26.6)        1.03 (0.57--1.85)   0.98            39 (31.70)   1.43 (0.88--2.33)    0.30
  CC           5 (2)                    7 (2.7)                1.41 (0.44--4.52)                       2 (2.5)          1.20 (0.22--6.43)                   4 (3.2)      1.64 (0.42--6.36)    
  rs2273773                                                                                                                                                                                   
  TT           124 (50.4)               133 (51.8)             1.00                                    35 (44.3)        1.00                                70 (56.9)    1.00                 
  TC           100 (40.6)               98 (38.1)              0.91 (0.63--1.32)   0.81                35 (44.3)        1.30 (0.75--2.23)   0.6             43 (35)      0.74 (0.47--1.19)    0.45
  CC           22 (8.9)                 26 (10.1)              1.10 (0.59--2.05)                       9 (11.4)         1.33 (1.56--3.18)                   10 (8.1)     0.85 (0.38--1.910)   
  rs4746720                                                                                                                                                                                   
  TT           79 (32.1)                94 (36.6)              1.00                                    26 (32.9)        1.00                                47 (38.2)    1.00                 
  TC           123 (50)                 124 (48.2)             0.85 (0.57--1.25)   0.50                42 (53.2)        1.13 (0.64--2.01)   0.63            58 (47.1)    0.76 (0.47--1.23)    0.45
  CC           44 (17.9)                39 (15.2)              0.74 (0.44--1.26)                       11 (13.9)        0.79 (0.35--1.76)                   18 (14.6)    0.71 (0.37--1.38)    

**Abbreviations:** AD, adenocarcinoma; NSCLC, non-small cell lung cancer; OR, odds ratio; SCC, squamous cell carcinoma; *SIRT1*, the silent information regulator 1.
